Cancer Clinical Trial
Official title:
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
NCT number | NCT03383094 |
Other study ID # | 170862 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 15, 2018 |
Est. completion date | June 2025 |
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Status | Recruiting |
Enrollment | 114 |
Est. completion date | June 2025 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - p16-positive squamous cell carcinoma of the pharynx, larynx or oral cavity - High-Intermediate Risk Disease, defined as: - T1-T3 N2 M0 or T3 N1 M0 or any stage III (T4 or N3) p16+ squamous cell carcinoma of the oropharynx (AJCC 8th edition staging system) - T1-2 N1-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the hypopharynx or larynx - T1-2 N2-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the nasopharynx - Inoperable T4 N0-3 M0 (stage IVA-IVB) p16+ squamous cell carcinoma of the oral cavity - Measurable disease based on RECIST 1.1 - Adequate hematologic function within 28 days prior to registration - Adequate renal and hepatic function - Female subject of childbearing potential should have a negative pregnancy test - Female subjects of childbearing potential must agree to use an adequate method of contraception for the course of the study - Male subjects must agree to use an adequate method of contraception for the course of the study Exclusion Criteria: - Prior malignancy within the past 3 years (except non-melanomatous skin cancer and early stage treated prostate cancer); - Prior head and neck radiation, chemotherapy, or immunotherapy; - Prior oncologic (radical) surgery to the primary site; - Documented evidence of distant metastases; - Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; - Transmural myocardial infarction within the last 6 months; - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; - Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration; - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects - Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. - Any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment; - Psychiatric/social situations that would limit compliance with study requirements - Hypersensitivity to pembrolizumab or any of its excipients. - Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. - Known history of, or any evidence of active, non-infectious pneumonitis. - Active infection requiring systemic therapy. - Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. - Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). - Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). - Has received a live vaccine within 30 days of planned start of study therapy. |
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | UC San Diego Moores Cancer Center | La Jolla | California |
United States | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Washington University School of Medicine, Siteman Cancer Center | Saint Louis | Missouri |
United States | H. Lee Moffitt Cancer Center & Research Facility | Tampa | Florida |
United States | University of Arizona Cancer Center | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Loren Mell, MD | Merck Sharp & Dohme LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | PD-L1 expression correlations | compare the outcomes with RT/pembrolizumab in patients with tumors as a function of PD-L1 expression. | 3 years | |
Primary | progression-free survival (PFS) | time from randomization to progression/relapse or death from any cause. | 3 years | |
Secondary | overall survival | time from randomization to death from any cause | 3 years | |
Secondary | Acute toxicity | Toxicities due to therapy occurring within 3 months of therapy completion based on CTCAE criteria using questionnaires | 3 months | |
Secondary | Late toxicity | Toxicity due to therapy occurring greater than 3 months after completion of therapy based on CTCAE criteria using questionnaires | 3 years | |
Secondary | Patterns of failure | Local and regional and distant recurrence of cancer and causes of death from competing events | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|